RAGE 229 NEW
| Price | $595 | $970 | $1170 |
| Package | 2mg | 5mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-07-24 |
Product Details
| Product Name: RAGE 229 | CAS No.: 2143072-85-7 |
| Supply Ability: 10g | Release date: 2025/07/24 |
Product Introduction
Bioactivity
| Name | RAGE 229 |
| Description | RAGE 229, N-(4-(7-cyano-4-(morpholin-4ylmethyl) quinolin-2-yl)phenyl)acetamide, is an orally active ctRAGE-DIAPH1 inhibitor. RAGE 229 can inhibit the intracellular RAGE signaling by inhibiting the interaction between the cytoplasmic tail of RAGE(ctRAGE) and Diaphanous-1(DIAPH1) [1]. |
| In vitro | RAGE229 demonstrates high affinity for ctRAGE, exhibiting a dissociation constant (K D) of 2 nM, and effectively inhibits smooth muscle cell (SMC) migration, as indicated by an inhibitory concentration 50 (IC 50) value of 26 nM [1]. In a Cell Migration Assay [1], employing SMCs at concentrations ranging from 0.00006 to 10 μM and an incubation time of 1.5 hours, RAGE229 consistently inhibited SMC migration, reaffirming its IC 50 value at 26 nM. |
| In vivo | RAGE229, administered via oral gavage at a dosage of 5 mg/kg twice daily for four days, effectively mitigates both short- and long-term diabetic complications in mice. Additionally, RAGE229, given either orally or intravenously (150, 50, and 15 ppm chow; 30, 10, and 3 mg/kg per day per mouse) and through intraperitoneal injections (5 mg/kg, every 12 hours for four total doses), significantly reduces plasma levels of pro-inflammatory markers TNF-α, IL-6, and CCL2/JE-MCP1 in diabetic mice. This results in decreased pathological and functional signs of diabetes-like kidney disease. In female CF-1 and male diabetic mice, a dosage of 5 mg/kg administered orally twice daily for four days lowered inflammation scores and the area of infarcts. Similarly, in C57BL/6J and BTBR ob/ob mice models, varying dosages (30, 10, and 3 mg/kg; 5 mg/kg) delivered orally or intravenously, including specific chow concentrations (150, 50, and 15 ppm) and intraperitoneal injections (5 mg/kg, every 12 hours for four doses), effectively reduced the concentrations of inflammatory markers CCL2, TNF-α, and IL-6. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Company Profile Introduction
TargetMol Chemicals Inc. is headquartered in Boston, MA, and specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a client base in 40+ countries, TargetMol has evolved into one of the biggest global research suppliers for compound libraries and small molecule compounds.
170+ Compound Libraries， 10000+ Noval Small Molecucles，16000+ Nature Compounds
TargetMol diligently updates and offers over 170 types of compound libraries and a wide range of high-quality research chemicals, including inhibitors, activators, natural products, peptides, antibodies , and novel life-science kits for laboratory and scientific use. In addition, our lab allows us to conduct CADD (computer-aided drug design) and chemical synthesis to meet the customization needs of our clients.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $73.00/50mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2025-07-25 | |
| $0.00/5mg |
VIP1Y
|
Guangzhou Tosun Pharmaceutical Ltd
|
2024-12-31 | |
| $85.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2025-07-09 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, Massachusetts, USA
INQUIRY